摘要
目的探讨急性冠状动脉综合征(ACS)患者经皮冠状动脉介入术(PCI)后血浆受体相互作用蛋白激酶3(RIPK3)水平及其与预后的关系。方法前瞻性选取2016年11月—2017年11月接受治疗的287例ACS患者作为研究对象。采用酶联免疫吸附法检测血浆RIPK3水平,并分析其与预后的关系。结果287例ACS患者随访期间主要不良心血管事件(MACE)发生率为23.00%。MACE组患者血浆RIPK3水平高于非MACE组,差异有统计学意义(P<0.05)。血浆RIPK3预测ACS患者预后的受试者工作特征(ROC)曲线下面积(AUC)、灵敏度、特异度分别为0.918、84.85%、95.02%。高RIPK3组患者预后不良发生率高于低RIPK3组,差异有统计学意义(P<0.05)。高RIPK3组患者中位生存时间低于低RIPK3组,差异有统计学意义(P<0.05)。COX回归分析显示慢性阻塞性肺疾病、发病至就诊时间、总胆红素、RIPK3与ACS患者预后关系密切。结论血浆RIPK3与ACS患者预后关系密切,检测血浆RIPK3水平有助于了解患者预后。
Aim To investigate the relationship between plasma receptor interaction protein kinase 3(RIPK3)and prognosis in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods A total of 287 ACS patients who were treated from November 2016 to November 2017 were selected as the study objects prospectively.Enzyme-linked immunosorbent assay was used to detect the level of RIPK3 in plasma and its relationship with prognosis was analyzed.Results The incidence of major adverse cardiovascular events(MACE)during follow-up of 287 patients with ACS was 23.00%.Plasma RIPK3 levels in patients with ACS with MACE were higher than those with non MACE,and the difference was statistically significant(P<0.05).The area under the receiver operating characteristic(ROC)curve(AUC),sensitivity,and specificity of RIPK3 in predicting the prognosis of patients with ACS were 0.918,84.85%,and 95.02%,respectively.The incidence of poor prognosis in the high RIPK3 group was higher than in the low RIPK3 group,and the difference was statistically significant(P<0.05).The median survival time of ACS patients in high-RIPK3 group was lower than that in low-RIPK3 group,and the difference was statistically significant(P<0.05).COX regression analysis showed that chronic obstructive pulmonary disease,time from onset to consultation,total bilirubin,and RIPK3 were closely related to the prognosis of patients with ACS.Conclusion Plasma RIPK3 is closely related to the prognosis of patients with ACS.Detection of plasma RIPK3 level is helpful to understand the prognosis of patients.
作者
刘莉莉
冯雷
杜超
王立君
张国瑞
LIU Lili;FENG Lei;DU Chao;WANG Lijun;ZHANG Guorui(Department of Cardiology,2.Department of Cardiothoratic Surgery,the Third Hospital of Shijiazhuang City,Hebei P rovince,Shijiazhuang,Hebei 050011,China)
出处
《中国动脉硬化杂志》
CAS
2021年第3期254-258,共5页
Chinese Journal of Arteriosclerosis
基金
河北省医学科学研究重点课题计划(20120435)。
